Array BioPharma Inc. (ARRY) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $13.95, down from yesterday’s close by -0.21%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.Fundamental Analysis
Array BioPharma Inc. (ARRY) currently trades with a market capitalization of $2.78 Billion. That value represents a market adjusting for revenues that have been falling by -24.25 % on a quarterly year/year basis as of the company’s last quarterly report.
You can get a sense of how sustainable that is by a levered free cash flow of -$45.3 Million over the past twelve months. Generally speaking, earnings are expected to fall in coming quarters. Analysts are forecasting earnings of -$0.23 on a per share basis this quarter. Perhaps, that suggests something about why 1.62% of the outstanding share supply is held by institutional investors.
We’ve taken a serious look at this stock from a fundamental perspective, but the tale of the tape may offer more hints about what lies under the surface. Looking at the stock’s movement on the chart, Array BioPharma Inc. recorded a 52-week high of $14.13. It is now trading 0.18% off that level. The stock is trading $11.59 its 50-day moving average by -2.36%. The stock carved out a 52-week low down at $6.73.
In recent action, Array BioPharma Inc. (ARRY) has made a move of +28.93% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 21.04, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 8.06% with $196.40 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of ARRY.